Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer 2024-11-15 09:55
Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease 2024-11-08 17:45
Harbour BioMed Announces Publication of the Phase I Study Results for Porustobart in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors 2024-10-10 11:04
Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024 2024-09-14 16:06
Harbour BioMed Announces 2024 Interim Results 2024-08-28 17:44
Harbour BioMed to Present the Latest Progress of the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024 2024-07-26 10:16
Harbour BioMed Announces Positive Profit Alert for 2024 Interim Results 2024-07-19 07:15
Harbour BioMed Announces Resubmission of Biologics License Application for Batoclimab to NMPA for Treatment of Generalized Myasthenia Gravis 2024-06-27 07:08
Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies 2024-05-23 07:23
Harbour BioMed Reports Full Year 2023 Financial Results 2024-03-28 22:10
Nona Biosciences Enters into Collaboration Agreement with Boostimmune in Antibody-Drug Conjugate Development 2024-02-27 09:23
Harbour BioMed Announces IND Clearance for HBM9027 in the U.S. 2024-01-24 12:40
Harbour BioMed Announces Positive Profit Alert 2024-01-19 12:52
Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC) 2023-12-15 07:30
Harbour BioMed Announces 2023 Interim Results 2023-08-28 17:08
Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors 2023-08-28 16:30
Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director 2023-08-08 16:10
Harbour BioMed Announces 2023 Interim Results Positive Profit Alert with the Enhancement of Value Driven by Innovation 2023-07-13 18:11
Harbour BioMed Announces Biologics License Application Acceptance of Batoclimab for Treatment of Generalized Myasthenia Gravis by NMPA 2023-06-29 21:26
Nona Biosciences Appoints Steve Arkinstall, D. Phil., as Chief Scientific Advisor 2023-06-07 09:00
1 2 3 4